Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
carboplatin
Class :
Antineoplastics, Alkylating agents
Brand Name :
No Data Available.
Synonyms :
carboplatin
Class :
Antineoplastics, Alkylating agents
Dosage Forms & StrengthsÂ
for reconstitution, lyophilized powderÂ
150mgÂ
injectable solutionÂ
10mg/mL (50, 150, 450, and 600 mg in vials)Â
Â
Combination treatment
:
360
mg/m²
Intravenous (IV)
every 4 weeks
300 mg/m² intravenous plus cyclophosphamide 600 mg/m² intravenous every 4Weeks
Dose Modifications
:
For SI units: Count in US units x 10^6/L Give 75% if Platelets <50000 Neutrophils <500 Give 125% if Platelets >100000 Neutrophils >2000 Give full dose if Platelets 50-100,000 Neutrophils 500-2000
CrCl 41-59 mL/min: 250 mg/m² Intravenous on day 1
CrCl 16-40 mL/min: 200 mg/m² Intravenous on day 1
CrCl <15 mL/min: usually not recommended
Dosage Forms & StrengthsÂ
for reconstitution, lyophilized powderÂ
150mgÂ
injectable solutionÂ
10mg/mL (50, 150, 450, and 600 mg in vials)Â
Refer to the adult dosing regimenÂ
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
carboplatin has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When loracarbef is used together with carboplatin, the risk or seriousness of nephrotoxicity is enhanced
When mometasone furoate is used together with carboplatin, this leads to enhanced risk or seriousness of adverse outcomes
When carboplatin is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
carboplatin leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
carboplatin leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
carboplatin leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
methoxypolyethylene glycol-epoetin betaÂ
combining carboplatin with methoxy polyethylene glycol-epoetin beta can raise the risk or severity of thrombosis
the risk or severity of nephrotoxicity and hypocalcemia can increase when carboplatin is combined with alendronic acid
carboplatin leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
carboplatin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
aminoglycosides may augment the ototoxic effect of carboplatin, particularly with higher doses of carboplatin
neomycin/polymyxin B/bacitracin topical
aminoglycosides may augment the ototoxic effect of carboplatin, particularly with higher doses of carboplatin
aminoglycosides may augment the ototoxic effect of carboplatin, particularly with higher doses of carboplatin
aminoglycosides may augment the ototoxic effect of carboplatin, particularly with higher doses of carboplatin
aminoglycosides may augment the ototoxic effect of carboplatin, particularly with higher doses of carboplatin
carboplatin leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
carboplatin: it may increase the risk or severity of CNS depression
carboplatin: it may increase the risk or severity of CNS depression
carboplatin: it may increase the risk or severity of CNS depression
carboplatin: it may increase the risk or severity of CNS depression
carboplatin: it may increase the risk or severity of CNS depression
carboplatin: it may increase the risk of nephrotoxicity with indobufen
carboplatin: it may decrease the excretion rate of moxisylyte
carboplatin may decrease the excretion rate of almasilate, leading to higher serum levels
By synergism effects, the toxicity of the other drug increases.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
both drug toxicity increases by synergism action
Increased risk of myelosuppressive effects
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both the drugs are combined, the risk or severity of adverse effects decreases    
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of infection  
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
May increase the nephrotoxic effects of aminoglycoside antibiotics
May increase the nephrotoxic effects of aminoglycoside antibiotics
It may enhance nephrotoxicity or ototoxicity when combined with pentamidine
the rate of excretion of inositol may be reduced
carboplatin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Actions and spectrum:Â
carboplatin is a chemotherapy drug that belongs to the class of platinum-containing antineoplastic agents. It works by binding to DNA and interfering with its replication, thereby inhibiting cell growth and division.
It has a very broad spectrum of activity against several types of cancer, including ovarian, lung, bladder, breast, and head and neck cancers. carboplatin is often used in combination with other chemotherapy drugs as part of a treatment regimen for these cancers. It is usually administered intravenously in a hospital or clinic setting.Â
Frequency definedÂ
>10%Â
Alopecia (2-49%)Â Â
Central neurotoxicity (5-26%)Â
Peripheral neuropathy (6-15%)Â
Asthenia (11-41%)Â
Anemia (14-90%)Â
Elevated AST (19-20%)Â
Neutropenia (21-96%)Â
Leukopenia (26-97%)Â
Elevated alkaline phosphatase (29-37%)Â
Thrombocytopenia (33-66%)Â
Magnesium loss (43-61%)Â
Nausea (81-93%)Â
Vomiting (81-93%)Â
1-10%Â
Elevated bilirubin (5%)Â Â
hypersensitivity reaction (2-9.2%)Â Â
Frequency not definedÂ
Visual disturbance (rare)Â
Post marketing ReportsÂ
StomatitisÂ
DehydrationÂ
Black Box Warning: Â
carboplatin can cause severe bone marrow suppression, leading to leukopenia, neutropenia, anaemia, and thrombocytopenia. The risk of myelosuppression is higher in patients with renal impairment and in those receiving a cumulative dose of more than 500 mg/m2.Â
Contraindication/Caution:Â
Contraindication:Â
carboplatin is contraindicated in patients with known severe hypersensitivity reactions to carboplatin, other platinum-containing compounds, or mannitol, which is an excipient in the formulation. It should not be used in severe bone marrow depression, bleeding disorders, or pre-existing kidney disease. Â
Caution:Â
Comorbidities:Â
Pregnancy consideration: Pregnancy Category DÂ
Lactation: safety and efficacy not established Â
Pregnancy category:Â
Pharmacology:Â
carboplatin is an antineoplastic agent that belongs to the class of platinum-containing compounds. It has a very broad spectrum of activity against several types of cancer and is used in the treatment of ovarian, lung, bladder, and other cancers.Â
carboplatin exerts its cytotoxic effects by forming covalent bonds with DNA, which leads to the inhibition of DNA synthesis and cell division. It induces apoptosis or programmed cell death in cancer cells, thereby preventing their proliferation.Â
carboplatin is activated intracellularly by hydrolysis, and the resulting positively charged species react with DNA. Its cytotoxicity is due to the formation of platinum-DNA adducts, which disrupt the structure and function of DNA. Â
Pharmacodynamics:Â
carboplatin is an antineoplastic agent that works by inhibiting DNA synthesis through the formation of covalent bonds with DNA. Specifically, it forms adducts with DNA bases, preventing DNA from being unwound and replicated. This leads to the inhibition of tumor cell proliferation and cell death.Â
carboplatin exhibits dose-dependent cytotoxicity, with a greater effect on rapidly dividing cells such as tumor cells. Its activity is cell cycle phase-nonspecific, meaning it can kill cells in any phase of the cell cycle.Â
The cytotoxic activity of carboplatin is dependent on its ability to form DNA adducts, which has several factors, including the concentration of the drug, the duration of exposure, and the rate of drug uptake by cells. Â
Pharmacokinetics:Â
AbsorptionÂ
carboplatin is administered intravenously and is rapidly distributed throughout the body Â
DistributionÂ
carboplatin has a volume of distribution of approximately 16 L, indicating that it is distributed extensively throughout the body tissues. It binds primarily to plasma proteins, with approximately 90% bound to albumin. Â
MetabolismÂ
carboplatin is not metabolized and is excreted unchanged by the kidneys. Â
Elimination and excretionÂ
carboplatin is eliminated primarily by the kidneys, with approximately 70% of the dose excreted unchanged in the urine within 24 hours. The elimination half-life of carboplatin is 1.1 to 1.5 hours.Â
Administration:Â
carboplatin is usually given intravenously (IV) in a hospital or clinic setting. The dosage and duration of administration depend on the patient’s individual factors, such as age, weight, overall health, and the condition being treated.
The drug is usually administered once every three to four weeks, and the dose may be adjusted based on the patient’s blood counts and response to treatment. Prior to each dose, the patient’s blood counts will be checked to ensure that they are within a safe range.Â
Patient information leafletÂ
Generic Name: carboplatinÂ
Pronounced: (car-bo-plat-in)Â Â
Why do we use carboplatin?Â
carboplatin is a chemotherapy drug that is used to treat several types of cancer, including ovarian cancer, lung cancer, bladder cancer, breast cancer, and others. It acts by interfering with the growth and spread of cancer cells in the body.
carboplatin is usually given in combination with other chemotherapy drugs to increase its effectiveness, and it is used as part of a conditioning regimen prior to stem cell transplant.
The exact dosage and treatment regimen will depend on the type and stage of cancer, as well as other factors such as the patient’s age and overall health status.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
